Search Results for: ustr
2014. Trade associations critiquing South Africa’s IPR policies, in Docket USTR-2013-0040
Special 301: NFTC puts plain packaging policies of Australia, EU, Thailand, UK, Ireland and New Zealand under the spotlight
The National Foreign Trade Council (NFTC) submission (7 February 2014, Docket USTR-2013-0040) to USTR’s 2014 Special 301 Review contains a section on plain packaging policies in the context of the protection of trademarks. Continue Reading
2014. Trade associations attacking Indian IPR policies, in Docket USTR-2013-0040
Alliance for Fair Trade with India (AFTI): Ground zero for trade sanctions against India 2014, BIO discussion of India 2014, IPO discussion of India 2014, NAM discussion of India 2014, NFTC discussion of India 2014, PhRMA discussion of India 2014,… Continue Reading
NFTC, a US trade association, asks USTR to sanction China for issuing and enforcing “junk patents” (2014 submission)
A February 7, 2014 Special 301 submission from the National Foreign Trade Council (NFTC) asks USTR to bring trade sanctions against China for granting and enforcing “junk patents.” The NFTC also wants patent enforcement to be strickly a private civil remedy (Contrast to the USTR demands that countries implement linkage between drug registration and patents), and complains about China rules that would require employers to more fairly compensation the Chinese inventors they Continue Reading
KEI files comments with USTR on 2014 Special 301
Attached in the February 7, 2014, KEI Special 301 Submission.
KEI was a web page with more context on the Special 301 reports, including links to several submissions, and all Special 301 Reports from 1989 to 2013 (all that exist), here: /ustr/special301 Continue Reading
US International Trade Commission Hearing, “Trade, Investment, and Industrial Policies in India: Effects on the US Economy”
Next week, the United States International Trade Commission (ITC) will hold a two-day hearing on “Trade, Investment, and Industrial Policies in India: Effects on the US Economy.” The first session will take place Wednesday, February 12, 2014 at 1:00pm and the second session will convene on Thursday, February 13, 2014 at 9:30am. Both sessions will be held at the ITC in the Main Hearing Room (room 101) at 500 E Street SW, Washington, DC.
Industry use of WHO Model List of Essential Medicines as defense against patent abuses
The following are some quotes by countries, companies, academics and other actors stating, suggesting or implying claiming that drugs not on the WHO Model List of Essential Medicines (WHO EML) should not be subject to a compulsory license.
Bayer. Political Principles.
http://www.bayer.com/en/innovation-requires-investment.aspx
Political Principles.
Innovation requires investment.
Good ideas must be worthwhile.
Blogs and Press coverage of Pharma/Medicine device industry lobbying on South Africa patent reform (pharmagate)
Boseley, Sarah. 17 January 2014. “South African pharma firms accused of planning to delay patents law reform.” The Guardian. http://www.theguardian.com/world/2014/jan/17/south-african-pharma-accused-delay-patents-law-reform
De Wet, Phillip. 17 January 2014. “Motsoaledi: Big pharma’s ‘satanic’ plot is genocide.” Mail & Guardian. http://mg.co.za/article/2014-01-16-motsoaledi-big-pharmas-satanic-plot-is-genocide/
TPP: Waxman letter to USTR opposing 12 year term of biologics exclusivity
In a 6 December 2013 letter, Representative Henry Waxman wrote to USTR Ambassador Michael Froman opposing USTR’s proposal of a term of 12 years of exclusivity for biologics in the Trans Pacific Partnership (TPP). The letter notes,
[w]hile I have worked closely with Senator Hatch on important health issues, including the generic drug law that we co-authored in 1984, I strongly disagreed that the United States should be proposing twelve years of exclusivity.